Total Funding
58
55
Total FundingSeries C raised
Growth Score
-4 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
16115
SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.
John Mulcahy: Co-founder and CEOPast Role: Stanford University, National Science Foundation Predoctoral Fellow
George Miljanich: Co-Founder & Chief Scientific OfficerPast Role: SiteOne Therapeutics, Founding President and CEO
About the Company
SiteOne Therapeutics is a biopharmaceutical company that develops novel therapeutics and diagnostics. They develop products that safely, effectively, and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Their lead therapeutic candidates are highly selective inhibitors of a
voltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals.
